As of 2025-10-18, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (43.09) USD. This relative valuation is based on P/E multiples. With the latest stock price at 11.01 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -491.3%.
The range of the Relative Valuation is (42.69) - (52.07) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 20.1x | 13.7x |
| Forward P/E multiples | 13.9x - 17.0x | 14.4x |
| Fair Price | (42.69) - (52.07) | (43.09) |
| Upside | -487.7% - -572.9% | -491.3% |
| Date | P/E |
| 2025-10-17 | -3.59 |
| 2025-10-16 | -3.71 |
| 2025-10-15 | -3.81 |
| 2025-10-14 | -3.57 |
| 2025-10-13 | -3.75 |
| 2025-10-10 | -3.59 |
| 2025-10-09 | -3.74 |
| 2025-10-08 | -3.68 |
| 2025-10-07 | -3.61 |
| 2025-10-06 | -3.70 |
| 2025-10-03 | -3.37 |
| 2025-10-02 | -3.37 |
| 2025-10-01 | -3.46 |
| 2025-09-30 | -3.90 |
| 2025-09-29 | -4.94 |
| 2025-09-26 | -2.58 |
| 2025-09-25 | -2.53 |
| 2025-09-24 | -2.55 |
| 2025-09-23 | -2.34 |
| 2025-09-22 | -2.51 |
| 2025-09-19 | -2.49 |
| 2025-09-18 | -2.56 |
| 2025-09-17 | -2.46 |
| 2025-09-16 | -2.43 |
| 2025-09-15 | -2.43 |
| 2025-09-12 | -2.70 |
| 2025-09-11 | -2.82 |
| 2025-09-10 | -2.72 |
| 2025-09-09 | -2.95 |
| 2025-09-08 | -2.91 |
| 2025-09-05 | -2.89 |
| 2025-09-04 | -2.90 |
| 2025-09-03 | -2.88 |
| 2025-09-02 | -2.93 |
| 2025-08-29 | -2.74 |
| 2025-08-28 | -2.83 |
| 2025-08-27 | -2.78 |
| 2025-08-26 | -2.82 |
| 2025-08-25 | -2.82 |
| 2025-08-22 | -2.88 |
| 2025-08-21 | -2.80 |
| 2025-08-20 | -2.88 |
| 2025-08-19 | -2.74 |
| 2025-08-18 | -2.66 |
| 2025-08-15 | -2.61 |
| 2025-08-14 | -2.52 |
| 2025-08-13 | -2.47 |
| 2025-08-12 | -2.24 |
| 2025-08-11 | -2.12 |
| 2025-08-08 | -2.25 |